Drug Trial Radar · NCT07136545
A Phase I/II Trial of HCB101 in Combination With Pembrolizumab for Patients With Platinum-Refractory, Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (SirH&N Trial)
Last checked: Nov 19, 2026Latest source record: Jul 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
50
Planned (sponsor's estimate)
Start
Aug 13, 2025
Primary completion
Dec 31, 2026
Study completion Dec 31, 2026
Sponsor
- Lead sponsor
- Taipei Veterans General Hospital, TaiwanGovernment (non-federal)
- Sponsor type
- Government (non-federal)
- Collaborators
- FBD Biologics Limited; National Taiwan University Hospital; Chang Gung Memorial Hospital
- First posted
- Aug 22, 2025
Design
- Study type
- Interventional
- Phase
- Phase 1 / Phase 2
- Allocation
- Not applicable (single group)
- Model
- Single group
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a non-randomized, open-label, dose-escalation and dose-expansion phase I/II clinical study to evaluate the safety, tolerability, and efficacy of HCB101 in combination with pembrolizumab in patients with platinum-refractory recurrent/metastatic HNSCC. The trial consists of two phases: the dose-escalation phase (I) and the dose-expansion phase (II). Subjects will receive a weekly single dose of HCB101 IV infusion over 60 (±10) minutes on Days 1, 8, and 15 in each 21-day cycle in combination with pembrolizumab (200 mg IV day 1; given every 21 days) until unacceptable AE(s), radiographic or clinically documented disease progression, withdrawal of consent, loss to follow-up, death, or termination of the study whichever occurs first.
Conditions
- HNSCC
Interventions
HCB101Drug
QW
PembrolizumabDrug
200 mg IV on Day 1, cycled every 21 days;
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of subjects with MTD of HCB101 in combination with pembrolizumabTime frame: 2 Years
- Overall Rate Response (ORR)Time frame: 2 Years
Locations
3 sites in 1 country. Site status is shown where the registry gives one.
Chang-Gung Memorial Hospital(Lin-Kou)
Taoyuan, Guishan District, Taiwan · Recruiting
National Taiwan University Hospital
Taipei, Taipei City, Taiwan · Recruiting
Taipei Veterans General Hospital
Taipei, Taipei City, Taiwan · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.